covid-19 experts patient Coronavirus

Santhera explores lonodelestat to treat ARDS in Covid-19 patients

Reading now: 431
www.pharmaceutical-technology.com

Swiss-based Santhera Pharmaceuticals has partnered with Cold Spring Harbor Laboratory (CSHL) to explore the use of lonodelestat (POL6014) as a potential treatment for acute respiratory distress syndrome (ARDS) caused by Covid-19.

CSHL researchers joined a new consortium of international non-clinical and clinical experts called ‘NETwork to target neutrophils in Covid-19’.

The consortium will analyse the role of neutrophils and neutrophil extracellular traps (NETs) in the Covid-19 pathology, while also investigating hNE and other targets for the treatment of the novel coronavirus infection.

NETs are macromolecular DNA structures and proteins that neutrophils can expel; hNE is generated by neutrophils during NETs formation.

Read more on pharmaceutical-technology.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA